MyFinsight
Home
Blog
About
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,743K
Free Cash flow
-$15,574K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from maturities of mark...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Deferred revenue
Payment of offering costs
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-13,921
-10,385
-16,457
-19,725
Depreciation and amortization
353
391
418
425
Noncash lease expense
390
387
384
383
Stock-based compensation
2,027
2,000
1,844
2,423
Amortization of premium and discount on marketable securities, net
313
388
188
49
Prepaid expenses and other current assets
102
561
-895
-287
Accounts payable
-154
-1,879
1,271
-2,429
Accrued expenses and other liabilities
1,921
-6,602
-515
-367
Deferred revenue
-5,704
-4,580
35,532
-
Long-term prepaid expenses and other long-term assets
-
-
0
-
Operating lease liabilities
71
68
65
63
Net cash used in operating activities
-15,574
-21,685
23,119
-19,115
Purchases of marketable securities
89,966
0
66,739
0
Proceeds from maturities of marketable securities
24,463
8,499
6,400
40,091
Purchases of property and equipment
0
0
0
0
Net cash (used in) provided by investing activities
-65,503
8,499
-60,339
40,091
Proceeds from issuance of common stock and pre-funded warrants
90,000
-
-
-
Proceeds from issuance of common stock in connection with the securities purchase agreement
-
-
24,875
-
Payment of withholding taxes related to stock-based compensation to employees
13
51
5
5
Payment of offering costs
4,367
294
0
0
Proceeds from issuance of common stock in connection with the exercise of stock options
85
31
16
0
Proceeds from issuance of common stock under employee stock purchase plan
115
-
58
0
Principal payments on finance lease liabilities
0
0
0
0
Net cash provided by (used in) financing activities
85,820
-314
24,944
-5
Net (decrease) increase in cash, cash equivalents and restricted cash
4,743
-13,500
-12,276
20,971
Cash, cash equivalents, and restricted cash at beginning of period
24,991
38,491
50,767
16,518
Cash, cash equivalents, and restricted cash at end of period
29,734
24,991
38,491
50,767
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$90,000K
Proceeds from issuance of
common stock under...
$115K
(25.00%↑ Y/Y)
Proceeds from issuance of
common stock in...
$85K
Net cash provided by
(used in) financing...
$85,820K
(69872.36%↑ Y/Y)
Canceled cashflow
$4,380K
Net (decrease)
increase in cash, cash...
$4,743K
(-64.28%↓ Y/Y)
Canceled cashflow
$81,077K
Payment of offering
costs
$4,367K
Payment of withholding
taxes related to...
$13K
(85.71%↑ Y/Y)
Proceeds from maturities
of marketable...
$24,463K
(-77.33%↓ Y/Y)
Stock-based compensation
$2,027K
(-73.49%↓ Y/Y)
Accrued expenses and
other liabilities
$1,921K
(191.56%↑ Y/Y)
Noncash lease expense
$390K
(-49.15%↓ Y/Y)
Depreciation and
amortization
$353K
(-59.33%↓ Y/Y)
Net cash (used in)
provided by investing...
-$65,503K
(-188.87%↓ Y/Y)
Net cash used in
operating activities
-$15,574K
(74.18%↑ Y/Y)
Canceled cashflow
$24,463K
Canceled cashflow
$4,691K
Purchases of marketable
securities
$89,966K
(163.62%↑ Y/Y)
Net loss
-$13,921K
(78.01%↑ Y/Y)
Deferred revenue
-$5,704K
Amortization of premium and
discount on marketable...
$313K
(133.58%↑ Y/Y)
Accounts payable
-$154K
(94.42%↑ Y/Y)
Prepaid expenses and
other current assets
$102K
(-92.60%↓ Y/Y)
Operating lease
liabilities
$71K
(171.00%↑ Y/Y)
Buy us a coffee